You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
據報國藥集團中國生物已佈局針對Omicron研發工作
阿思達克 12-10 17:02
《上海證券報》引述國藥集團消息報道,國藥集團中國生物在3條技術路線上,均已佈局針對新冠變種病毒Omicron的研發工作。 北京生物所、武漢生物所將對Delta株、Beta株和已上市滅活疫苗做交叉中和實驗;國藥集團中國生物研究院已啓動Omicron株基因圖譜設計,正在構建細胞株;國藥集團所屬中生復諾健也啓動了Omicron株疫苗研發。國藥集團中國生物會在第一時間做好所有變異株疫苗的儲備工作。 目前,國藥集團中國生物研發的新冠疫苗已經形成「一代有效、二代備用」的格局。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account